Microbial metabolites regulating PD-L1 and checkpoint pathways: translational implications

Recent advances in microbiome research reveal that microbial metabolites directly regulate PD-L1 expression and influence checkpoint immunotherapy outcomes. Multi-cohort analyses of over 1,300 patients show that elevated short-chain fatty acids (SCFAs), indole derivatives, and secondary bile acids modulate PD-L1 and T-cell activity through HDAC inhibition, STAT3 phosphorylation, and AhR signaling. High fecal butyrate correlates with a 2.4-fold higher response rate and 6.3-month improvement in progression-free survival during PD-1 blockade. Conversely, dysbiosis-associated metabolites, including lipopolysaccharide (LPS) and succinate, induce PD-L1 hyperexpression and immune resistance. Metabolomic profiling now achieves AUCs of 0.82-0.89 in predicting immunotherapy response, outperforming tumor mutational burden and PD-L1 IHC. These findings establish microbial metabolites as active immunoregulatory mediators, offering new translational strategies for microbiome-informed immunotherapy personalization and biomarker integration in oncology.